MedPath

open label, randomized, pilot study on the activity of olanzapine with or without delayed dexamenthasone versus dexamenthasone alone for the prevention of delayed nausea and vomiting in patients with gynecologic cancers receiving carboplatin and paclitaxel-based chemotherapy and guidline-directed prophylactic anti-emetics

Phase 1
Conditions
Patients with gynecologic tumors candidate to chemotherapy with carboplatinum and paclitaxel
Therapeutic area: Diseases [C] - Cancer [C04]
Registration Number
EUCTR2013-005309-30-IT
Lead Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Female
Target Recruitment
75
Inclusion Criteria

patient with diagnosis of gynecologic cancer not pretreate with chemoterapy
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 30
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 45

Exclusion Criteria

patients scheduled to receive chemotherapy, brain metastases, patients who receive another antipsychotic agent, performance status >2

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath